Treatments · Entity Annotation Prototype (beta)

1articles mentioning treatments

1treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: antibody-drug conjugate (ADC) therapies ×

antibody-drug conjugate (ADC) therapies

This treatment is selected. Its supporting articles are shown below.

antibody-drug conjugate (ADC) therapies1

Articles mentioning antibody-drug conjugate (ADC) therapies

1 articles · page 1 of 1

53 Assessing the mechanism of action (MOA) of tisotumab vedotin (TV) in head and neck squamous cell carcinoma (HNSCC) with digital pathology analysis of H&E images from innovaTV207 part C

jitc · abstract · 2025-11-04 · 1 matching annotations

77.2%

antibody-drug conjugate (ADC) therapies Tisotumab vedotin HNSCC Pfizer Seagen Inc.Genmab Nucleus Global

…r cells in the TME can support elucidation of complex MOAs with antibody-drug conjugate (ADC) therapies. TV is a tissue factor-directed ADC hypothesized to drive apopt…

Browse treatments

antibody-drug conjugate (ADC) therapies

Articles mentioning antibody-drug conjugate (ADC) therapies

53 Assessing the mechanism of action (MOA) of tisotumab vedotin (TV) in head and neck squamous cell carcinoma (HNSCC) with digital pathology analysis of H&E images from innovaTV207 part C